Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

MIGM AND MIGD RECEPTOR SIGNALING IN B LYMPHOMA APOPTOSIS

Award Number: K01CA094027
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TECHNICAL ASSISTANCE
PERIOD OF PERFORMANCE START DATE: 05/10/2002
PERIOD OF PERFORMANCE END DATE: 04/30/2007

Group Awards By:

View Award Description

MIGM AND MIGD RECEPTOR SIGNALING IN B LYMPHOMA APOPTOSIS - DESCRIPTION (provided by applicant): Our broad aim is to better understand the roles of surface IgM and IgD (slgM and slgD respectively) receptors in B lymphomas and normal cells. Using anti-mu and anti-delta antibodies to crosslink and activate slgM and slgD receptors respectively, we established that anti-mu and not anti-delta induced growth arrest and apoptosis in B lymphoma cells. Although anti-mu, and anti-delta both stimulate c-Myc, only anti-mu, ultimately ablates c-Myc protein expression and mediates a large induction of p27Kip1 protein. We also demonstrated that c-Myc protein expression is controlled through the ITAM and we recently established PI-3K regulation as the mediator of anti-mu, and anti-delta action. Therefore, our first aim is to explore the role of ITAMS and accessory BCR proteins in PI-3K recruitment and signaling. This will be performed by using CD8-Ig-alpha fusion protein constructs which contain ITAM and non-ITAM mutations first using immunohistochemical then molecular methods. We will also directly test our hypothesis that aborted apoptotic signaling via the slgD receptor results from its failure to co-localize negative regulators which could include adapter proteins, kinase(s), phosphatase(s) or even possibly ITIM-containing co-receptors. Our second aim is to directly establish the role(s) of PI-3K pathway proteins in anti-mu driven growth arrest and apoptosis. We will subclone active and dominant negative PI-3K modulators and effector cDNAs into HIV-TAT fusion vectors. These fusion proteins will be transduced into lymphoma cell lines and primary cells to determine their roles and the hierarchy of their influence on slgM or slgD receptor signaling. Our third aim is to further explore and contrast positive and negative signaling in BCR induced apoptosis. We recently observed that anti-mu massively stimulates PTEN protein expression, whereas anti-delta does not. Therefore, I will establish the mechanisms that regulate PTEN protein expression following BCR engagement and determine its role in BCR mediated outcomes. Transduction of dominant negative PTEN should render lymphoma cells resistant to anti-mu mediated growth arrest whereas transduction of active PTEN should mimic or augment the anti-mu (apoptotic) and anti-delta (pro-apoptotic) responses. Our last aim is to compare and contrast selected gene expression with slgM and slgD receptor signaling. Using a novel gene expression technique, RAGE, we recently observed that anti-mu, specifically modulates a number of cDNAs. We will perform kinetic analysis of the expression of their corresponding proteins and determine their role(s) in the anti-mu effect. Together, these studies will delineate proteins and signaling events, modules and programs initiated by the surface IgM or surface IgD receptors to effect survival, growth arrest and/or apoptosis in B-lymphoma cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2006 ( Subtotal = $161,730 )
2006	2006	UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL SCHOOLS	220 ARCH ST OFFICE LEVEL 2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Biology Research	000	6	4/26/2006	NON-COMPETING CONTINUATION	$161,730
														Subtotal = $161,730

Issue Date FY: 2005 ( Subtotal = $161,730 )
2005	2005	UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL SCHOOLS	737 WEST LOMBARD STREET	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Biology Research	000	5	4/7/2005	NON-COMPETING CONTINUATION	$161,730
														Subtotal = $161,730

Issue Date FY: 2004 ( Subtotal = $156,661 )
2004	2004	UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL SCHOOLS	737 WEST LOMBARD STREET	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Research Manpower	001	4	9/13/2004	SUPPLEMENT FOR EXPANSION	$25,331
2004	2004	AMERICAN NATIONAL RED CROSS HEADQUARTERS	600 A FOREST POINT CIRCLE	CHARLOTTE	NC	28273	MECKLENBURG	USA	Cancer Biology Research	000	3	5/10/2004	NON-COMPETING CONTINUATION	$13,885
2004	2004	UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL SCHOOLS	737 WEST LOMBARD STREET	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Biology Research	000	4	9/10/2004	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$117,445
														Subtotal = $156,661

Issue Date FY: 2003 ( Subtotal = $107,478 )
2003	2003	AMERICAN NATIONAL RED CROSS HEADQUARTERS	600 A FOREST POINT CIRCLE	CHARLOTTE	NC	28273	MECKLENBURG	USA	Cancer Biology Research	000	2		NON-COMPETING CONTINUATION	$107,478
														Subtotal = $107,478

Issue Date FY: 2002 ( Subtotal = $104,891 )
2002	2002	AMERICAN NATIONAL RED CROSS HEADQUARTERS	600 A FOREST POINT CIRCLE	CHARLOTTE	NC	28273	MECKLENBURG	USA	Cancer Biology Research	000	1	5/9/2002	NEW	$104,891
														Subtotal = $104,891

Grand Total All Awards = $692,490

Top

All Categories

About

Search

Reports

Data Submission

Award Information

MIGM AND MIGD RECEPTOR SIGNALING IN B LYMPHOMA APOPTOSIS

Award Number: K01CA094027

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TECHNICAL ASSISTANCE

PERIOD OF PERFORMANCE START DATE: 05/10/2002

PERIOD OF PERFORMANCE END DATE: 04/30/2007

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer